Najam (Naj) Sharif, PhD, DSc, FARVO, FBPhS, FAOPT has >34-years’ pharmaceutical drug discovery research experience. His 22-year tenure at Alcon resulted in his contributions to the discovery, characterization, development and US FDA approvals of Travatan®, Patanol®, Emedine® to treat glaucoma/ocular hypertension and allergic conjunctivitis, respectively. He is currently a Vice President at Santen Inc USA where he recently helped acquire the PRESERFLO Microshunt for lowering and controlling IOP. Dr. Sharif is the recipient of the inaugural Dr. Roger Vogel award for ocular pharmaceutical research from the ARVO Foundation, the recipient of the “Sir James Black Award” for contributions to drug discovery from the British Pharmacological Society, and the awardee of the Ernst Barany Prize for contributions to ocular pharmacology from the International Society for Eye Research (ISER). He is an Adjunct Professor at multiple global universities and has published >210 scientific articles, edited 2 books and holds 24 issued US/EU patents.
Ocular pharmacology; drug discovery; receptors and enzymes.